
Conference Coverage
about 22 hours ago
AOA 2026: Managing dry eye with contact lensesLatest Content

AOA 2026: The latest updates in keratoconus treatment advancements

Thea Pharma launches Zolymbus in the US as preservative-free bimatoprost gel

AOA 2026: Patient-reported outcomes with a novel daily disposable toric contact lens

AOA 2026: Managing dry eye with contact lenses

AOA 2026: An optometrist’s guide to interventional glaucoma

Shorts










Podcasts
Optometry Times Digital Edition





Continuing Medical Education
All News

The emerging technology offers a new paradigm for treating a group of eye diseases.

Joe Shovlin, OD, FAAO, outlines the management and treatment of corneal infections in one of his Optometry's Meeting presentations.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, discussed his AOA 2026 presentation "Eye of the Needle Returns: Navigating the Patient’s Journey Receiving Intravitreal Injections."

A cross-sectional study of nearly 10,000 nursing home residents found a clear dose-response relationship between vision loss and cognitive impairment, with blind residents having nearly 3 times the odds of cognitive loss compared with those with normal vision.

A Johnson & Johnson Vision poster found a novel multifocal toric daily disposable contact lens delivered visual acuity within 1 letter and comparable fitting success to an existing nontoric multifocal lens, extending coverage to presbyopes with up to 1.75D astigmatism.

Melody Tavakoli, OD, said that she has found that workhorse in Johnson & Johnson's Oasys lens family.

A systematic review of 22 studies found Demodex infestation strongly associated with MGD, with MGD prevalence reaching 92% to 99% in symptomatic Demodex blepharitis and significantly worse meibomian gland structure and function in infested patients.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosli (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.

Anna Tichenor, OD, PhD, FAAO, details her poster – one of AOA 2026's Top Five posters – that identified how quickly and how meaningfully patients experience symptom improvement, and which types of symptoms are affected.

A VA case report documents rapid PDR progression to intravitreal anti-VEGF treatment in a patient 6 months after semaglutide initiation, reinforcing AOA monitoring guidance for GLP-1 patients with preexisting DR.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his portion of the "Myopia Matters: Managing Risk, Vision Loss and Control" presentation.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

Expanded astigmatism parameters are expected for PRECISION1, PRECISION7, and TOTAL30 contact lenses.











































